Hyaluronic Acid in Treatment and Prevention of Postoperative Complications After Endoscopic Surgery for Benign Prostatic Hyperplasia

The aim of the investigation was to evaluate the clinical effect of URO-HYAL, a hyaluronic acid preparation, in the treatment of dysuric disorders and prevention of complications after transurethral endoscopic surgery for benign prostatic hyperplasia (BPH).

Materials and Methods. A randomized study was carried out in two groups of patients operated for BPH using transurethral enucleation with bipolar and bipolar transurethral resection of the prostate. In the postoperative period, 51 patients of the main group underwent 6 intravesical instillations of URO-HYAL, 150 patients of the control group received standard antibiotic therapy. The clinical effect was assessed 1, 3, 6, 12 months after the surgery on the basis of the complex urological examination results and adenoma bed bioptate histology.

Results. Histological examination of the adenoma bed bioptate of patients after endoscopic surgery for BPH has shown that intravesical administration of URO-HYAL in the postoperative period enables almost 2.5-fold reduction of the wound surface epithelization period. One month after the surgery there have been significantly less manifestations of dysuric disorders, higher life quality and no late postoperative cicatricial complications in the main group as compared to the control.

Conclusion. Treatment with URO-HYAL preparation after endoscopic surgery for BPH has been proved by our investigations to be pathogenically reasonable, clinically effective, and especially important for patients with a complicated course of BPH.

1. Martov A.G., Merinov D.S., Kornienko S.I., et al. Postoperative urological complications in transurethral electrosurgical interventions on the prostate for adenoma. Urologiya 2006; 2: 25–31.
2. Al-Shukri S.Kh., Tkachuk I.N. The prophylactics of irritational disorders of urination after transurethral resection of prostate gland in patients with benign hyperplasia of prostate gland. Nefrologiya 2008; 12(4): 67–71.
3. Souverein P.C., Erkens J.A., de la Rosette J.J., Leufkens H.G., Herings R.M. Drug treatment of benign prostatic hyperplasia and hospital admission for BPH-related surgery. Europ Urol 2003; 43(5): 528–534, http://dx.doi.org/10.1016/S0302-2838(03)00089-7.
4. Oelke M., Bachmann A., Descazeaud A., Emberton M., Gravas S., Michel M.C., N’Dow J., Nordling J., de la Rosette J.J. Guidelines on male lower urinary tract symptoms (LUTS), including benign prostatic obstruction (BPO). Geneva: EAU; 2012, http://uroweb.org/wp-content/uploads/11_Male_LUTS.pdf.
5. Markov A.V., Lukianov I.V., Loran О.В. Complex therapy of irritative voiding disorders after transurethral resection of the prostate and adenomectomy. Urologiya 2007; 4: 41–44.
6. Urologiya. Klinicheskie rekomendatsii. 3-e izd [Urology. Clinical guidelines. 3rd ed.]. Moscow: GEOTAR-Media; 2014.
7. Shormanov I.S., Ryzhkov A.I. Hyperbaric oxygenation in the treatment of urination disorders after transurethral resection of benign prostatic hyperplasia. Fundamentalnie issledovania 2011; 1: 205–212.
8. Loran О.В., Lukiyanov I.V., Markov A.V. Combined therapy of voiding irritative disorders after surgical treatment of benign prostatic hyperplasia with Andro-Gin. Urologiya 2005; 3: 15–18.
9. Kamalov A.A., Efremov E.A., Dorofeev S.D., Mel’nik Ya.I., Okhobotov D.A. Vitaprost forte in the treatment of patients with prostatic adenoma. Urologiya 2007; 3: 39–47.
10. Yaroshenko V.P., Miller A.M. Irritational disorders of urination after transurethral electroresection in patients with benign prostatic hyperplasia. Effektivnaya farmakoterapiya. Urologiya i nefrologiya 2011; 1: 27–28.
11. Tkachuk V.N., Tkachuk I.N. Efficacy of Vitaprost forte in the treatment of patients with prostatic adenoma. Urologiya 2014; 2(13): 63–67.
12. Zakhmatov Yu.M., Varentsov G.I., Otvetchikov A.I., Kornev A.I. Dinamika IPSS posle razlichnykh vidov operativnogo lecheniya DGPZh. V kn.: Materialy X rossiyskogo s”ezda urologov [IPSS dynamics after different types of surgery for BPN. In: Materials of the 10th Russian Conference of Urologists]. Moscow; 2002; p. 112–114.
13. Kudrjavcev Ju.V., Kirpatovskiy V.I., Perepanova T.S., Khazan P.L. Glycosaminoglycans stabilizer zinc hyaluronate use in experimental modeling of acute bacterial and interstitial cystitis. Eksperimental’naya i klinicheskaya urologiya 2011; 1: 39–44.
14. Glybochko P.V., Alyaev Yu.G., Gadzhieva Z.K., et al. Application of hyaluronic acid in the treatment of chronic cystitis. Effektivnaya farmakoterapiya. Urologiya i nefrologiya 2011; 5: 30–35.
15. Morales A., Emerson L., Nickel J.C., Lundie M. Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. J Urol 1996; 156(1): 45–48, http://dx.doi.org/10.1016/S0022-5347(01)65933-0.
16. Constantinides C., Manousakas T., Nikolopoulos P., Stanitsas A., Haritopoulos K., Giannopoulos A. Prevention of recurrent bacterial cystitis by intravesical administration of hyaluronic acid: a pilot study. BJU Int 2004; 93(9): 1262–1266, http://dx.doi.org/10.1111/j.1464-410X.2004.04850.x.
17. Lipovac M., Kurz C., Reithmayr F., Verhoeven H.C., Huber J.C., Imhof M. Prevention of recurrent bacterial urinary tract infections by intravesical instillation of hyaluronic acid. Int J Gynaecol Obstet 2007; 96(3): 192–195, http://dx.doi.org/10.1016/j.ijgo.2006.11.025.
18. Sevryukov F.A. Kompleksnye mediko-sotsial’nye i kliniko-ekonomicheskie aspekty profilaktiki i lecheniya dobrokachestvennoy giperplazii predstatel’noy zhelezy. Avtoref. dis. … dokt. med. nauk [Complex medical-social and clinical-economic aspects of prevention and treatment of benign prostatic hyperplasia. DSc Thesis]. Moscow; 2012.

Sorokin D.A., Puchkin A.B., Semenitchev D.V., Karpukhin I.V., Kochkin A.D., Zorin D.G., Sevryukov F.A. Hyaluronic Acid in Treatment and Prevention of Postoperative Complications After Endoscopic Surgery for Benign Prostatic Hyperplasia. Sovremennye tehnologii v medicine 2015; 7(4): 97, https://doi.org/10.17691/stm2015.7.4.13